What's new — Hypertension¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 1 |
| last month | 6 |
| last 2 months | 27 |
| last 3 months | 31 |
| last 6 months | 45 |
| last year | 79 |
| older than a year | 723 |
| undated in PubMed | 1 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-11-01 | KDOQI Commentary on the 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults — Am J Kidney Dis ([PMID 42907045](https://pubmed.ncbi.nlm.nih.gov/42907045/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-05 | Optimizing Blood Pressure Care in Patients With Resistant Hypertension: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee — J Am Coll Cardiol ([PMID 42831847](https://pubmed.ncbi.nlm.nih.gov/42831847/){target="_blank" rel="noopener"}) | guidelines, resistant-and-refractory-hypertension |
| 2026-10-02 | 2026 THS guidelines for the management of hypertension in older adults: Developed by the task force on the management of hypertension of the Taiwan Hypertension Society (THS) and endorsed by the Taiwan Society of Cardiology (TSOC), Taiwan Association of Gerontology and Geriatrics (TAGG), and Taiwan Society of Family Medicine (TSFM) — J Formos Med Assoc ([PMID 42926177](https://pubmed.ncbi.nlm.nih.gov/42926177/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-02 | Bangladesh HEARTS: Lessons Learned from a National Hypertension Control Program, 2018-2026 — Glob Heart ([PMID 42921236](https://pubmed.ncbi.nlm.nih.gov/42921236/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-10-02 | 2026 International Society of Hypertension Global Hypertension Practice Guidelines — J Hypertens ([PMID 42909506](https://pubmed.ncbi.nlm.nih.gov/42909506/){target="_blank" rel="noopener"}) | blood-pressure-targets, definition-measurement-and-diagnosis, guidelines, secondary-hypertension |
| 2026-10-02 | Updated practical guide for validation studies of automated cuff blood pressure monitors according to the Universal Standard by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (ISO 81060-2:2018) and Amendments 1:2020 and 2:2024 — J Hypertens ([PMID 42853222](https://pubmed.ncbi.nlm.nih.gov/42853222/){target="_blank" rel="noopener"}) | definition-measurement-and-diagnosis |
| 2026-10-01 | A Pilot Randomized Study of NAT2 and YEATS4 Pharmacogenetic Return of Results in Adults with Hypertension and African Ancestry: The GUARDD-US PGx Study — Clin Pharmacol Ther ([PMID 42894271](https://pubmed.ncbi.nlm.nih.gov/42894271/){target="_blank" rel="noopener"}) | genetics-and-monogenic-forms |
| 2026-10-01 | Postpartum Blood Pressure After Hypertensive Disorders of Pregnancy and Subsequent Cardiovascular Disease: A Population-Based Cohort Study — BJOG ([PMID 42888852](https://pubmed.ncbi.nlm.nih.gov/42888852/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2026-10-01 | Planned Antihypertensive Deprescribing in Long-Term Care Residents: A Systematic Review of Randomized Evidence — Drugs Aging ([PMID 42888381](https://pubmed.ncbi.nlm.nih.gov/42888381/){target="_blank" rel="noopener"}) | special-populations |
| 2026-10-01 | Optimal exercise modalities and doses for blood pressure management in adults with prehypertension and hypertension: A systematic review and Bayesian network meta-analysis — Maturitas ([PMID 42887271](https://pubmed.ncbi.nlm.nih.gov/42887271/){target="_blank" rel="noopener"}) | lifestyle-and-dietary-management |
| 2026-10-01 | Telehealth and Digital Interventions for Type 2 Diabetes and Hypertension in Latin America and the Caribbean: A Systematic Review and Meta-Analysis — Telemed J E Health ([PMID 42886602](https://pubmed.ncbi.nlm.nih.gov/42886602/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-10-01 | Global Prevalence of Adherence to Antihypertensives and Associated Moderating Factors Among Adults With Hypertension: A Meta-Analysis — J Am Heart Assoc ([PMID 42885806](https://pubmed.ncbi.nlm.nih.gov/42885806/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-10-01 | Epidemiology of uncontrolled and treatment‑resistant hypertension: a registry‑based observational study — Blood Press ([PMID 42872749](https://pubmed.ncbi.nlm.nih.gov/42872749/){target="_blank" rel="noopener"}) | resistant-and-refractory-hypertension |
| 2026-10-01 | Aldosterone-Producing Lesions Harboring ATP1A1 and ATP2B3 Mutations: An International Multicenter Study — Hypertension ([PMID 42866865](https://pubmed.ncbi.nlm.nih.gov/42866865/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-10-01 | Potential under-recognition of primary aldosteronism in young adults with hypertension — J Hum Hypertens ([PMID 42864372](https://pubmed.ncbi.nlm.nih.gov/42864372/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-10-01 | Blood pressure targets in adults with hypertension — Cochrane Database Syst Rev ([PMID 42861682](https://pubmed.ncbi.nlm.nih.gov/42861682/){target="_blank" rel="noopener"}) | blood-pressure-targets |
| 2026-10-01 | Guideline-Directed Treatment Eligibility and Burden of Untreated Stage-1 Hypertension Under the 2025 American College of Cardiology/American Heart Association Hypertension Guideline: Insights From NHANES 2015 to 2020 — J Am Heart Assoc ([PMID 42858041](https://pubmed.ncbi.nlm.nih.gov/42858041/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-01 | A qualitative study on the practicality of guideline recommended office blood pressure measurement in primary care — Aust J Gen Pract ([PMID 42849428](https://pubmed.ncbi.nlm.nih.gov/42849428/){target="_blank" rel="noopener"}) | definition-measurement-and-diagnosis |
| 2026-09-04 | Using electronic clinical decision support in primary care to enhance identification of primary aldosteronism: a protocol for the CONSEP cluster-randomised controlled trial — J Hum Hypertens ([PMID 42697927](https://pubmed.ncbi.nlm.nih.gov/42697927/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-09-04 | Implementation of Clinical Hypertension Guidelines and Single Pill Combinations: A Qualitative Study in Australian General Practice — Am J Hypertens ([PMID 42693929](https://pubmed.ncbi.nlm.nih.gov/42693929/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-09-02 | Blood pressure targets for hypertension in people with diabetes mellitus — Cochrane Database Syst Rev ([PMID 42788405](https://pubmed.ncbi.nlm.nih.gov/42788405/){target="_blank" rel="noopener"}) | blood-pressure-targets, guidelines, special-populations |
| 2026-09-02 | Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria — Kidney Int ([PMID 42778148](https://pubmed.ncbi.nlm.nih.gov/42778148/){target="_blank" rel="noopener"}) | clinical-trials-landscape, pharmacological-therapy, special-populations |
| 2026-09-02 | Comparison of oral enalapril-hydrochlorothiazide and oral nifedipine in treating postpartum hypertension: an open label randomized controlled trial — Am J Obstet Gynecol MFM ([PMID 42767560](https://pubmed.ncbi.nlm.nih.gov/42767560/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2026-09-01 | Joint Expert Consensus on the Sodium Reduction Policy in Taiwan: A Collaborative Declaration by the Taiwan Hypertension Society (THS), Taiwan Society of Cardiology (TSOC), International Life Sciences Institute (ILSI), and Nutrition Society of Taiwan (NST) — Acta Cardiol Sin ([PMID 42780603](https://pubmed.ncbi.nlm.nih.gov/42780603/){target="_blank" rel="noopener"}) | lifestyle-and-dietary-management |
| 2026-09-01 | 2025 AHA/ACC blood pressure guideline and HEARTS 2.0: implications for the future evolution of integrated cardiovascular-kidney-metabolic care in the Americas — Rev Panam Salud Publica ([PMID 42756877](https://pubmed.ncbi.nlm.nih.gov/42756877/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-01 | Intensification of blood pressure lowering therapeutics based on diuretics versus usual management for uncontrolled hypertension in patients with moderate to severe chronic kidney disease (THINK): protocol for an open label, two-parallel group, cluster randomised controlled, superiority, phase 3 trial — BMJ Open ([PMID 42754276](https://pubmed.ncbi.nlm.nih.gov/42754276/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-09-01 | Implications of the 2025 AHA/ACC hypertension guideline on hypertension prevalence, treatment eligibility and blood pressure control in Nigeria: a cross-sectional comparative study — BMJ Public Health ([PMID 42688995](https://pubmed.ncbi.nlm.nih.gov/42688995/){target="_blank" rel="noopener"}) | guidelines |
| 2026-08-03 | Achieved systolic blood pressure and cardiovascular outcomes in advanced chronic kidney disease — Clin Kidney J ([PMID 42865623](https://pubmed.ncbi.nlm.nih.gov/42865623/){target="_blank" rel="noopener"}) | special-populations |
| 2026-08-03 | Hypertensive disorders of pregnancy and the risk for hypertension and cardiovascular and kidney disease. International Society of Hypertension position paper, endorsed by the World Hypertension League and European Society of Hypertension — J Hypertens ([PMID 42695459](https://pubmed.ncbi.nlm.nih.gov/42695459/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2026-08-02 | Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial — Circulation ([PMID 42666029](https://pubmed.ncbi.nlm.nih.gov/42666029/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-08-02 | Baxdrostat: First Approval — Drugs ([PMID 42625106](https://pubmed.ncbi.nlm.nih.gov/42625106/){target="_blank" rel="noopener"}) | pharmacological-therapy, resistant-and-refractory-hypertension |
| 2026-08-01 | AVS-referenced diagnostic performance of (68)Ga-Pentixafor PET/CT for detecting unilateral disease in primary aldosteronism: a systematic review and meta-analysis — Front Endocrinol (Lausanne) ([PMID 42687933](https://pubmed.ncbi.nlm.nih.gov/42687933/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-08-01 | Association Between Follow-Up Mean Blood Pressure and Blood Pressure Control: A Meta-Regression Analysis of 101 Randomized Trials — Hypertension ([PMID 42605672](https://pubmed.ncbi.nlm.nih.gov/42605672/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-08-01 | Integrating hypertension care into the existing HIV services package in Botswana (InterCARE): a pair-matched, cluster-randomised, type 2 hybrid effectiveness-implementation trial — Lancet Glob Health ([PMID 42586107](https://pubmed.ncbi.nlm.nih.gov/42586107/){target="_blank" rel="noopener"}) | adherence-and-implementation, clinical-trials-landscape, special-populations |
| 2026-08-01 | Prevalence of adherence to antihypertensive treatment: a comparison of drug biochemical analysis and the self-report scale — Clin Hypertens ([PMID 42564271](https://pubmed.ncbi.nlm.nih.gov/42564271/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-07-03 | Association of a CCB-Related Pharmacogenomics-Guided Strategy with Blood Pressure Outcomes and Short-Term Safety in Chinese Patients with Hypertension: A Secondary Exploratory Analysis of Two Randomized Cohorts — Drug Healthc Patient Saf ([PMID 42553612](https://pubmed.ncbi.nlm.nih.gov/42553612/){target="_blank" rel="noopener"}) | genetics-and-monogenic-forms |
| 2026-07-02 | 2026 ISH guidelines for the management of hypertension in Africa: the International Society of Hypertension (ISH) African Regional Advisory Group and the Pan African Society of Cardiology (PASCAR) — J Hypertens ([PMID 42554264](https://pubmed.ncbi.nlm.nih.gov/42554264/){target="_blank" rel="noopener"}) | guidelines |
| 2026-07-01 | Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage: A Single-Center Prospective Cohort Study — Eur J Neurol ([PMID 42397158](https://pubmed.ncbi.nlm.nih.gov/42397158/){target="_blank" rel="noopener"}) | hypertensive-emergencies |
| 2026-07-01 | Innovative Device-Based Treatments for Hypertension — Am J Hypertens ([PMID 41344842](https://pubmed.ncbi.nlm.nih.gov/41344842/){target="_blank" rel="noopener"}) | device-and-interventional-therapy |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — J Am Coll Cardiol ([PMID 42265997](https://pubmed.ncbi.nlm.nih.gov/42265997/){target="_blank" rel="noopener"}) | lifestyle-and-dietary-management, special-populations |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — Circulation ([PMID 42263157](https://pubmed.ncbi.nlm.nih.gov/42263157/){target="_blank" rel="noopener"}) | special-populations |
| 2026-06-03 | Terminal Digit Preference and Threshold Avoidance in Digital Blood Pressure Measurements During Pregnancy: Secondary Analysis of Data From the CLIP and PRECISE Cohorts — JMIR Mhealth Uhealth ([PMID 42234864](https://pubmed.ncbi.nlm.nih.gov/42234864/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2026-06-01 | Polygenic risk score translation across diverse populations — Front Cardiovasc Med ([PMID 42395874](https://pubmed.ncbi.nlm.nih.gov/42395874/){target="_blank" rel="noopener"}) | genetics-and-monogenic-forms, special-populations |
| 2026-05-15 | Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program — EuroIntervention ([PMID 42137915](https://pubmed.ncbi.nlm.nih.gov/42137915/){target="_blank" rel="noopener"}) | device-and-interventional-therapy |
| 2026-05-15 | Effect of intensive blood pressure control in patients with resistant hypertension: insights from the STEP trial — Eur J Prev Cardiol ([PMID 40796327](https://pubmed.ncbi.nlm.nih.gov/40796327/){target="_blank" rel="noopener"}) | resistant-and-refractory-hypertension |
| 2026-05-02 | Endogenous and exogenous determinants of sex differences in blood pressure — NPJ Cardiovasc Health ([PMID 42185679](https://pubmed.ncbi.nlm.nih.gov/42185679/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-05-01 | Managing Blood Pressure Beyond Viral Suppression for Patient and Provider Perspectives on Antihypertensive Medication Adherence in HIV Care: A Qualitative Study — Res Sq ([PMID 42239779](https://pubmed.ncbi.nlm.nih.gov/42239779/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-05-01 | Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial — Lancet HIV ([PMID 42067280](https://pubmed.ncbi.nlm.nih.gov/42067280/){target="_blank" rel="noopener"}) | special-populations |
| 2026-04-28 | Diagnosis and Management of Resistant Hypertension: A Review — JAMA ([PMID 41870448](https://pubmed.ncbi.nlm.nih.gov/41870448/){target="_blank" rel="noopener"}) | clinical-trials-landscape, device-and-interventional-therapy, red-flags-and-safety-concerns, resistant-and-refractory-hypertension |
| 2026-04-22 | Persistent Renin Suppression After Unilateral Adrenalectomy for Primary Aldosteronism: Implications for Adverse Outcome? — J Clin Endocrinol Metab ([PMID 41175007](https://pubmed.ncbi.nlm.nih.gov/41175007/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-04-02 | A Review of Clinical Trial and Meta-Analyses of BP Treatment Strategies for Patients with Orthostatic Hypotension: Blood Pressure Management in Patients with Hypertension and Orthostatic Hypotension — Curr Hypertens Rep ([PMID 42033492](https://pubmed.ncbi.nlm.nih.gov/42033492/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-04-01 | Is It Time to Retire Aldosterone Suppression Testing? — Am J Hypertens ([PMID 40887827](https://pubmed.ncbi.nlm.nih.gov/40887827/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-03-07 | Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial — Lancet ([PMID 41794437](https://pubmed.ncbi.nlm.nih.gov/41794437/){target="_blank" rel="noopener"}) | clinical-trials-landscape, pharmacological-therapy, resistant-and-refractory-hypertension |
| 2026-03-03 | Single-Pill Combination Olmesartan/Amlodipine/Hydrochlorothiazide Safety and Effectiveness in Older Patients with Hypertension: Pooled Analysis of Post-Approval Observational Studies — Adv Ther ([PMID 41915114](https://pubmed.ncbi.nlm.nih.gov/41915114/){target="_blank" rel="noopener"}) | pharmacological-therapy |
| 2026-03-01 | Aldosterone and Impaired Nocturnal Blood Pressure Decline in Primary Aldosteronism — J Am Heart Assoc ([PMID 41804894](https://pubmed.ncbi.nlm.nih.gov/41804894/){target="_blank" rel="noopener"}) | definition-measurement-and-diagnosis |
| 2026-02-26 | (title unavailable) — ** ([PMID 31577399](https://pubmed.ncbi.nlm.nih.gov/31577399/){target="_blank" rel="noopener"}) | guidelines |
| 2026-02-06 | Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines — Hypertension ([PMID 41645899](https://pubmed.ncbi.nlm.nih.gov/41645899/){target="_blank" rel="noopener"}) | guidelines, secondary-hypertension |
| 2026-02-02 | Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT — Hypertension ([PMID 41717679](https://pubmed.ncbi.nlm.nih.gov/41717679/){target="_blank" rel="noopener"}) | pharmacological-therapy |
| 2026-02-01 | Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention — Am J Obstet Gynecol ([PMID 41707896](https://pubmed.ncbi.nlm.nih.gov/41707896/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2026-02-01 | Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trial — Trials ([PMID 41689048](https://pubmed.ncbi.nlm.nih.gov/41689048/){target="_blank" rel="noopener"}) | clinical-trials-landscape, special-populations |
Trials — what has moved¶
63 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 9 |
| trial records updated in the last 2 months | 15 |
| trial records updated in the last 3 months | 20 |
| trial records updated in the last 6 months | 28 |
| trial records updated in the last year | 43 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pr | PHASE3 | 218 | Least Square Mean Difference for Change From Baseline in Ambulatory 24 | 2 | 95 | 0 |
| 2026-06-03 | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotr | PHASE2 | 60 | Placebo-adjusted Change From Baseline in Automated Office Blood Pressu | 2 | 47 | 0 |
| 2026-04-30 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Mode | PHASE1, PHASE2 | 36 | Number of Participants With Adverse Events (AEs) | 0 | 16 | 0 |
| 2025-12-17 | A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropi | PHASE2 | 48 | Number of Participants With Serum Total Cortisol Level Before and Afte | 0 | 12 | 0 |
| 2025-07-09 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequa | PHASE2 | 663 | Indapamide: Change From Baseline at Month 3 in 24-hour Mean SBP Assess | 33 | 278 | 2 |
| 2024-12-27 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With | PHASE2 | 394 | Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM | 44 | 342 | 3 |
| 2023-09-15 | SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyra | NA | 337 | Change in Systolic Blood Pressure as Measured by 24-hour Ambulatory Bl | 77 | 244 | 3 |
| 2023-06-28 | A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rH | PHASE2 | 275 | Change From Baseline in Mean Seated Systolic BP (SBP) | 10 | 40 | 0 |
| 2023-03-21 | A Research Study to Show the Effect of Aprocitentan in the Treatment o | PHASE3 | 730 | Change From Baseline to Week 4 of Double-blind Treatment in Mean Troug | 128 | 160 | 11 |
| 2021-05-27 | SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study | NA | 366 | Number of Participants With Major Adverse Events (MAE) Defined as a Co | 74 | 304 | 3 |
| 2020-04-13 | Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With | PHASE2 | 1659 | Change From Baseline to End of Double-blind Treatment in Sitting Diast | 3 | 151 | 0 |
31 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| guidelines | 2026-11-01 | 12 | 61 |
| resistant-and-refractory-hypertension | 2026-10-05 | 7 | 49 |
| adherence-and-implementation | 2026-10-02 | 9 | 64 |
| blood-pressure-targets | 2026-10-02 | 4 | 45 |
| definition-measurement-and-diagnosis | 2026-10-02 | 4 | 75 |
| secondary-hypertension | 2026-10-02 | 12 | 69 |
| genetics-and-monogenic-forms | 2026-10-01 | 4 | 45 |
| hypertension-in-pregnancy | 2026-10-01 | 6 | 56 |
| lifestyle-and-dietary-management | 2026-10-01 | 4 | 54 |
| special-populations | 2026-10-01 | 11 | 85 |
| clinical-trials-landscape | 2026-09-02 | 7 | 43 |
| pharmacological-therapy | 2026-09-02 | 8 | 70 |
| device-and-interventional-therapy | 2026-07-01 | 3 | 48 |
| hypertensive-emergencies | 2026-07-01 | 3 | 37 |
| epidemiology-and-burden | 2026-05-02 | 4 | 42 |
| patient-experience-and-advocacy | 2026-05-01 | 2 | 39 |
| red-flags-and-safety-concerns | 2026-04-28 | 2 | 57 |
| pathophysiology | 2025-10-02 | 0 | 73 |
| overview | 2025-10-01 | 0 | 57 |
| risk-and-outcomes | 2025-10-01 | 0 | 39 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.